Characteristics of fibrinolytic disorders in acute promyelocytic leukemia

References

• Rahme R, Thomas X, Recher C, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422–2424. doi: 10.1038/leu.2014.240
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–1134. doi: 10.1038/leu.2011.78
   PubMed Web of Science ®Google Scholar
• Jacomo RH, Melo RA, Souto FR, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007;92(10):1431–1432. doi: 10.3324/haematol.10874
   PubMed Web of Science ®Google Scholar
• Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004–1009. doi: 10.1016/j.leukres.2013.05.007
   PubMed Web of Science ®Google Scholar
• Tenno T, Oberg F, Mackman N, et al. PML/RARalpha plays a role for basal activity and retinoid-induced repression of the tissue factor promoter in acute promyelocytic leukemia cells. Thromb Haemost. 2003;90(5):930–939.
   PubMed Web of Science ®Google Scholar
• Yan J, Wang K, Dong L, et al. PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association. Proc Natl Acad Sci USA. 2010;107(8):3716–3721. doi: 10.1073/pnas.0915006107
   PubMed Web of Science ®Google Scholar
• Bennett B, Booth NA, Croll A, et al. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol. 1989;71(4):511–517. doi: 10.1111/j.1365-2141.1989.tb06311.x
   PubMed Web of Science ®Google Scholar
• Graf M, Reif S, Hecht K, et al. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis. Am J Hematol. 2005;79(1):26–35. doi: 10.1002/ajh.20337
   PubMed Web of Science ®Google Scholar
• Avvisati G, ten Cate JW, Sturk A, et al. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol. 1988;70(1):43–48. doi: 10.1111/j.1365-2141.1988.tb02432.x
   PubMed Web of Science ®Google Scholar
• Sakata Y, Murakami T, Noro A, et al. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood. 1991;77(9):1949–1957.
   PubMed Web of Science ®Google Scholar
• Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994–1004. doi: 10.1056/NEJM199904013401303
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Z, Jiang M, et al. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res. 2011;35(7):879–884. doi: 10.1016/j.leukres.2010.11.008
   PubMed Web of Science ®Google Scholar
• Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 1994;269(33):21198–21203.
   PubMed Web of Science ®Google Scholar
• Hajjar KA, Acharya SS. Annexin II and regulation of cell surface fibrinolysis. Ann NY Acad Sci. 2000;902:265–271. doi: 10.1111/j.1749-6632.2000.tb06321.x
   PubMed Web of Science ®Google Scholar
• Ohsawa M, Koyama T, Shibakura M, et al. Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells. Leukemia. 2000;14(5):941–943. doi: 10.1038/sj.leu.2401755
   PubMed Web of Science ®Google Scholar
• Zhou J, Shi J, Hou J, et al. Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost. 2010;8(4):773–782. doi: 10.1111/j.1538-7836.2010.03763.x
   PubMed Web of Science ®Google Scholar
• Wassenaar T, Black J, Kahl B, et al. Acute promyelocytic leukaemia and acquired α-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematol Oncol. 2008;26(4):241–246. doi: 10.1002/hon.867
   PubMed Web of Science ®Google Scholar
• Takada A, Watahiki Y, Takada Y. Effects of fibrin on the enhanced activation of plasminogen by urokinase and tissue plasminogen activator: role of cross-link. Thromb Res. 1986;41(5):605–613. doi: 10.1016/0049-3848(86)90357-9
   PubMed Web of Science ®Google Scholar
• Lacroix R, Plawinski L, Robert S, et al. Leukocyte- and endothelial-derived microparticles: a circulating source for fibrinolysis. Haematologica. 2012;97(12):1864–1872. doi: 10.3324/haematol.2012.066167
   PubMed Web of Science ®Google Scholar
• Roy A. Estimating correlation coefficient between two variables with repeated observations using mixed effects model. Biom J. 2006;48(2):286–301. doi: 10.1002/bimj.200510192
   PubMed Web of Science ®Google Scholar
• Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays. 2003;25(12):1220–1228. doi: 10.1002/bies.10360
   PubMed Web of Science ®Google Scholar
• Falanga A, Consonni R, Marchetti M, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92(1):143–151.
   PubMed Web of Science ®Google Scholar
• Cao M, Li T, He Z, et al. Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia. Blood. 2017;129(13):1855–1864. doi: 10.1182/blood-2016-09-739334
   PubMed Web of Science ®Google Scholar
• Nakasaki T, Wada H, Mori Y, et al. Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia. Am J Hematol. 2000;64(3):145–150. doi: 10.1002/1096-8652(200007)64:3<145::AID-AJH1>3.0.CO;2-P
   PubMed Web of Science ®Google Scholar
• Tallman MS, Lefebvre P, Baine RM, et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost. 2004;2(8):1341–1350. doi: 10.1111/j.1538-7836.2004.00787.x
   PubMed Web of Science ®Google Scholar
• Zhu J, Guo WM, Yao YY, et al. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia. 1999;13(7):1062–1070. doi: 10.1038/sj.leu.2401448
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhou H, Wang J, et al. Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thromb Res. 2002;106(1):63–70. doi: 10.1016/S0049-3848(02)00075-0
   PubMed Web of Science ®Google Scholar
• Brownstein C, Deora AB, Jacovina AT, et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood. 2004;103(1):317–324. doi: 10.1182/blood-2003-04-1304
   PubMed Web of Science ®Google Scholar
• Luo M, Hajjar KA. Annexin A2 system in human biology: cell surface and beyond. Semin Thromb Hemost. 2013;39(4):338–346. doi: 10.1055/s-0033-1334143
   PubMed Web of Science ®Google Scholar